Trimetrexate (BioDeep_00000008521)
Secondary id: BioDeep_00000858453
human metabolite blood metabolite
代谢物信息卡片
5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine
化学式: C19H23N5O3 (369.1801)
中文名称: 三甲曲沙
谱图信息:
最多检出来源 Homo sapiens(blood) 17.65%
分子结构信息
SMILES: CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC
InChI: InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)
描述信息
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [PubChem]
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01A - Agents against amoebiasis and other protozoal diseases
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists
D000890 - Anti-Infective Agents > D000935 - Antifungal Agents
D009676 - Noxae > D000963 - Antimetabolites
D000970 - Antineoplastic Agents
Same as: D06238
同义名列表
15 个代谢物同义名
5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine; Trimetrexate monohydrate, monoacetate; Monohydrate, monoacetate trimetrexate; Ipsen brand OF trimetrexate; Trimetrexate ipsen brand; Hydrate, trimetrexate; Trimetrexate hydrate; Trimetrexic acid; trimetrexate; Neutrexin; JB 11; JB-11; TMQ; TMX; Trimetrexate
数据库引用编号
17 个数据库交叉引用编号
- ChEBI: CHEBI:9737
- KEGG: C11154
- PubChem: 5583
- HMDB: HMDB0015288
- Metlin: METLIN68879
- DrugBank: DB01157
- ChEMBL: CHEMBL119
- Wikipedia: Trimetrexate
- MeSH: Trimetrexate
- chemspider: 5381
- CAS: 251301-18-5
- CAS: 52128-35-5
- PMhub: MS000022146
- PubChem: 13336
- PDB-CCD: TMQ
- NIKKAJI: J22.060D
- KNApSAcK: 9737
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Allen T Hopper, Adam Brockman, Andy Wise, Julie Gould, Jennifer Barks, Joshua B Radke, L David Sibley, Yongmao Zou, Stephen Thomas. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
Journal of medicinal chemistry.
2019 02; 62(3):1562-1576. doi:
10.1021/acs.jmedchem.8b01754. [PMID: 30624926] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Shrikanta Chattopadhyay, Roni Tamari, Sang H Min, Rongbao Zhao, Eugenia Tsai, I David Goldman. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
The oncologist.
2007 Jul; 12(7):808-15. doi:
10.1634/theoncologist.12-7-808. [PMID: 17673612] - Eran Bram, Ilan Ifergan, Assaf Shafran, Bluma Berman, Gerrit Jansen, Yehuda G Assaraf. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Cancer chemotherapy and pharmacology.
2006 Dec; 58(6):826-34. doi:
10.1007/s00280-006-0230-9. [PMID: 16612649] - Jia-Ping Lai, Xi-Wen He, Feng Chen. Separation and determination of the antitumor drug piritrexim by molecularly imprinted microspheres in high-performance liquid chromatography.
Analytical and bioanalytical chemistry.
2003 Sep; 377(1):208-13. doi:
10.1007/s00216-003-2086-8. [PMID: 12845402] - Shuqian Liu, Lifu Song, Robert Bevins, Ogheneruemu Birhiray, Jeffrey A Moscow. The murine-reduced folate carrier gene can act as a selectable marker and a suicide gene in hematopoietic cells in vivo.
Human gene therapy.
2002 Sep; 13(14):1777-82. doi:
10.1089/104303402760293600. [PMID: 12396629] - A H Sarris, A Phan, M Duvic, J Romaguera, P McLaughlin, O Mesina, K King, L J Medeiros, G Z Rassidakis, B Samuels, F Cabanillas. Trimetrexate in relapsed T-cell lymphoma with skin involvement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2002 Jun; 20(12):2876-80. doi:
10.1200/jco.2002.08.006. [PMID: 12065565] - P F Kelly, J Carrington, A Nathwani, E F Vanin. RD114-pseudotyped oncoretroviral vectors. Biological and physical properties.
Annals of the New York Academy of Sciences.
2001 Jun; 938(?):262-76; discussion 276. doi:
10.1111/j.1749-6632.2001.tb03596.x. [PMID: 11458516] - J A Allay, H T Spencer, S L Wilkinson, J A Belt, R L Blakley, B P Sorrentino. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors.
Blood.
1997 Nov; 90(9):3546-54. doi:
10.1182/blood.v90.9.3546. [PMID: 9345038] - A R Hanauske. The development of new chemotherapeutic agents.
Anti-cancer drugs.
1996 Aug; 7 Suppl 2(?):29-32. doi:
. [PMID: 8862708] - B Fulton, A J Wagstaff, D McTavish. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia.
Drugs.
1995 Apr; 49(4):563-76. doi:
10.2165/00003495-199549040-00007. [PMID: 7789290] - A Kheradpour, E Berman, E Göker, J T Lin, W P Tong, J R Bertino. A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia.
Cancer investigation.
1995; 13(1):36-40. doi:
10.3109/07357909509024893. [PMID: 7834472] - R S Witte, B Y Yeap, D L Trump. Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.
Investigational new drugs.
1994; 12(3):255-8. doi:
10.1007/bf00873968. [PMID: 7896546] - G F Fleming, R L Schilsky. Antifolates: the next generation.
Seminars in oncology.
1992 Dec; 19(6):707-19. doi:
". [PMID: 1462168] - L A Dethloff, J R Watkins. Chronic toxicity of the anticancer agent trimetrexate in rats.
Fundamental and applied toxicology : official journal of the Society of Toxicology.
1992 Jul; 19(1):6-14. doi:
10.1016/0272-0590(92)90022-a. [PMID: 1397803] - R S Witte, P Elson, G T Bryan, D L Trump. Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.
Investigational new drugs.
1992 Apr; 10(1):51-4. doi:
10.1007/bf01275483. [PMID: 1535065] - W W Li, J T Lin, W P Tong, T M Trippett, M F Brennan, J R Bertino. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas.
Cancer research.
1992 Mar; 52(6):1434-8. doi:
NULL. [PMID: 1371715] - G W Amsden, S F Kowalsky, G D Morse. Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS.
The Annals of pharmacotherapy.
1992 Feb; 26(2):218-26. doi:
10.1177/106002809202600217. [PMID: 1532518] - M J Graziano, S N Kim, J R MacDonald, J R Watkins. Toxicity of the anticancer folate antagonist trimetrexate in rats.
Fundamental and applied toxicology : official journal of the Society of Toxicology.
1992 Jan; 18(1):115-25. doi:
10.1016/0272-0590(92)90203-t. [PMID: 1534775] - T Taguchi, S Tsukagoshi, H Furue, H Niitani, K Ohta, H Ariyoshi, K Hasegawa, H Majima, I Nakao, M Yasutomi. [Phase I study of CI-898. CI-898 Study Group].
Gan to kagaku ryoho. Cancer & chemotherapy.
1991 Aug; 18(10):1599-612. doi:
NULL. [PMID: 1831340] - M C Broughton, S F Queener. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.
Antimicrobial agents and chemotherapy.
1991 Jul; 35(7):1348-55. doi:
10.1128/aac.35.7.1348. [PMID: 1929292] - G R Hudes, F LaCreta, J Walczak, P Tinsley, S Litwin, R L Comis, P J O'Dwyer. Pharmacokinetic study of trimetrexate in combination with cisplatin.
Cancer research.
1991 Jun; 51(12):3080-7. doi:
NULL. [PMID: 1828188] - R C Sharma, Y G Assaraf, R T Schimke. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells.
Cancer research.
1991 Jun; 51(11):2949-59. doi:
". [PMID: 1674447] - N A Dawson, M E Costanza, A H Korzun, G H Clamon, M Pollak, N J Vogelzang, R W Carey, L Norton. Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Medical and pediatric oncology.
1991; 19(4):283-8. doi:
10.1002/mpo.2950190413. [PMID: 1829134] - B K Wong, T F Woolf, T Chang, L R Whitfield. Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog.
Drug metabolism and disposition: the biological fate of chemicals.
1990 Nov; 18(6):980-6. doi:
NULL. [PMID: 1981548] - P W Tinsley, F P LaCreta. Improved chromatographic method for the determination of trimetrexate in urine.
Journal of chromatography.
1990 Aug; 529(2):468-72. doi:
10.1016/s0378-4347(00)83856-6. [PMID: 2146281] - M S Rhee, M Balinska, M Bunni, D G Priest, G F Maley, F Maley, J Galivan. Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
Cancer research.
1990 Jul; 50(13):3979-84. doi:
. [PMID: 2162250] - C J Allegra, J Jenkins, R B Weiss, F Balis, J C Drake, J Brooks, R Thomas, G A Curt. A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
Investigational new drugs.
1990 May; 8(2):159-66. doi:
10.1007/bf00177251. [PMID: 2143500] - W W Bullen, T Chang, L R Whitfield. High-performance liquid chromatographic assay for trimetrexate in human plasma.
Journal of chromatography.
1990 Mar; 526(1):266-72. doi:
10.1016/s0378-4347(00)82509-8. [PMID: 2140367] - H Arkin, T Ohnuma, B A Kamen, J F Holland, S Vallabhajosula. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
Cancer research.
1989 Dec; 49(23):6556-61. doi:
. [PMID: 2573416] - Y G Assaraf, A Molina, R T Schimke. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate.
The Journal of biological chemistry.
1989 Nov; 264(31):18326-34. doi:
. [PMID: 2572592] - J Galivan, M S Rhee, T B Johnson, R Dilwith, M G Nair, M Bunni, D G Priest. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
The Journal of biological chemistry.
1989 Jun; 264(18):10685-92. doi:
10.1016/s0021-9258(18)81677-5. [PMID: 2525127] - Y G Assaraf, A Molina, R T Schimke. A fluorescein-methotrexate-based flow cytometric bioassay for measurement of plasma methotrexate and trimetrexate levels.
Analytical biochemistry.
1989 May; 178(2):287-93. doi:
10.1016/0003-2697(89)90640-4. [PMID: 2526605] - C N Sternberg, A Yagoda, H Scher, G Bosl, D Dershaw, K Rosado, C Houston, R Rosenbluth, V Vinciguerra, B Boselli. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.
European journal of cancer & clinical oncology.
1989 Apr; 25(4):753-4. doi:
10.1016/0277-5379(89)90215-0. [PMID: 2523810] - Y G Assaraf, A Molina, R T Schimke. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Journal of the National Cancer Institute.
1989 Feb; 81(4):290-4. doi:
10.1093/jnci/81.4.290. [PMID: 2521520] - M G Kris, R W D'Acquisto, R J Gralla, M T Burke, L D Marks, M P Fanucchi, R T Heelan. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
American journal of clinical oncology.
1989 Feb; 12(1):24-6. doi:
10.1097/00000421-198902000-00006. [PMID: 2536213] - L B Grochow, D A Noe, G B Dole, E K Rowinsky, D S Ettinger, M L Graham, W P McGuire, R C Donehower. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Journal of the National Cancer Institute.
1989 Jan; 81(2):124-30. doi:
10.1093/jnci/81.2.124. [PMID: 2909752] - G R Hudes, F LaCreta, R J DeLap, A J Grillo-Lopez, R Catalano, R L Comis. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Cancer chemotherapy and pharmacology.
1989; 24(2):117-22. doi:
10.1007/bf00263132. [PMID: 2525077] - J F Bishop, D Raghavan, I N Olver, P Reece, R Morris, M L Friedlander. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
Cancer chemotherapy and pharmacology.
1989; 24(4):246-50. doi:
10.1007/bf00257627. [PMID: 2526692] - L B Grochow, D A Noe, D S Ettinger, R C Donehower. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
Cancer chemotherapy and pharmacology.
1989; 24(5):314-20. doi:
10.1007/bf00304765. [PMID: 2758561] - A S Alberts, G Falkson, M Badata, A P Terblanche, E U Schmid. Trimetrexate in advanced carcinoma of the esophagus.
Investigational new drugs.
1988 Dec; 6(4):319-21. doi:
10.1007/bf00173651. [PMID: 2976410] - J A Kovacs, C J Allegra, S Kennedy, J C Swan, J Drake, J E Parrillo, B Chabner, H Masur. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
The American journal of tropical medicine and hygiene.
1988 Nov; 39(5):491-6. doi:
10.4269/ajtmh.1988.39.491. [PMID: 2973755] - E A Eisenhauer, B C Zee, J L Pater, W R Walsh. Trimetrexate: predictors of severe or life-threatening toxic effects.
Journal of the National Cancer Institute.
1988 Oct; 80(16):1318-22. doi:
10.1093/jnci/80.16.1318. [PMID: 2971818] - J L Grem, S S Ellenberg, S A King, D D Shoemaker. Correlates of severe or life-threatening toxic effects from trimetrexate.
Journal of the National Cancer Institute.
1988 Oct; 80(16):1313-8. doi:
10.1093/jnci/80.16.1313. [PMID: 2971817] - J A Stewart, J J McCormack, W Tong, J B Low, J D Roberts, A Blow, L R Whitfield, L D Haugh, W R Grove, A J Lopez. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Cancer research.
1988 Sep; 48(17):5029-35. doi:
. [PMID: 2970294] - G J Rosenthal, G W Weigand, D R Germolec, J A Blank, M I Luster. Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action.
Journal of immunology (Baltimore, Md. : 1950).
1988 Jul; 141(2):410-6. doi:
. [PMID: 2968399] - F E Young, S L Nightingale. FDA's newly designated treatment INDs.
JAMA.
1988 Jul; 260(2):224-5. doi:
NULL. [PMID: 2838651] - C J Allegra, B A Chabner, C U Tuazon, D Ogata-Arakaki, B Baird, J C Drake, H Masur. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS).
Seminars in oncology.
1988 Apr; 15(2 Suppl 2):46-9. doi:
. [PMID: 2966985] - J A Kovacs, C J Allegra, J C Swan, J C Drake, J E Parrillo, B A Chabner, H Masur. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.
Antimicrobial agents and chemotherapy.
1988 Apr; 32(4):430-3. doi:
10.1128/aac.32.4.430. [PMID: 2967669] - P Rogers, C J Allegra, R F Murphy, J C Drake, H Masur, D G Poplack, B A Chabner, J E Parrillo, H C Lane, F M Balis. Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome.
Antimicrobial agents and chemotherapy.
1988 Mar; 32(3):324-6. doi:
10.1128/aac.32.3.324. [PMID: 2966610] - C J Allegra, B A Chabner, C U Tuazon, D Ogata-Arakaki, B Baird, J C Drake, J T Simmons, E E Lack, J H Shelhamer, F Balis. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
The New England journal of medicine.
1987 Oct; 317(16):978-85. doi:
10.1056/nejm198710153171602. [PMID: 2958710] - C J Allegra, K Hoang, G C Yeh, J C Drake, J Baram. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.
The Journal of biological chemistry.
1987 Oct; 262(28):13520-6. doi:
. [PMID: 2443493] - F M Balis, R Patel, E Luks, K M Doherty, J S Holcenberg, C Tan, G H Reaman, J Belasco, L J Ettinger, S Zimm. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
Cancer research.
1987 Sep; 47(18):4973-6. doi:
. [PMID: 2957048] - D H Ho, W P Covington, S S Legha, R A Newman, I H Krakoff. Clinical pharmacology of trimetrexate.
Clinical pharmacology and therapeutics.
1987 Sep; 42(3):351-6. doi:
10.1038/clpt.1987.160. [PMID: 2957140] - S F Queener, M S Bartlett, M A Jay, M M Durkin, J W Smith. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.
Antimicrobial agents and chemotherapy.
1987 Sep; 31(9):1323-7. doi:
10.1128/aac.31.9.1323. [PMID: 2445281] - M P Fanucchi, T D Walsh, M Fleisher, G Lokos, L Williams, C Cassidy, P Vidal, T C Chou, D Niedzwiecki, C W Young. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Cancer research.
1987 Jun; 47(12):3303-8. doi:
NULL. [PMID: 2953412] - P A Reece, R G Morris, J F Bishop, I N Olver, D Raghavan. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
Cancer research.
1987 Jun; 47(11):2996-9. doi:
NULL. [PMID: 2952262] - R F Branda, J K Carney, C A Perlmutter, A L Moore, J J McCormack. Inhibition of lymphocyte nucleic acid metabolism and antibody production by trimetrexate.
Biochemical pharmacology.
1987 May; 36(10):1605-12. doi:
10.1016/0006-2952(87)90043-8. [PMID: 2954554] - J A Kovacs, C J Allegra, B A Chabner, J C Swan, J Drake, M Lunde, J E Parrillo, H Masur. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
The Journal of infectious diseases.
1987 May; 155(5):1027-32. doi:
10.1093/infdis/155.5.1027. [PMID: 2951446] - C J Allegra, J A Kovacs, J C Drake, J C Swan, B A Chabner, H Masur. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent.
The Journal of experimental medicine.
1987 Mar; 165(3):926-31. doi:
10.1084/jem.165.3.926. [PMID: 2950200] - C J Allegra, J A Kovacs, J C Drake, J C Swan, B A Chabner, H Masur. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
The Journal of clinical investigation.
1987 Feb; 79(2):478-82. doi:
10.1172/jci112837. [PMID: 2948969] - J T Lin, A R Cashmore, M Baker, R N Dreyer, M Ernstoff, J C Marsh, J R Bertino, L R Whitfield, R Delap, A Grillo-Lopez. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Cancer research.
1987 Jan; 47(2):609-16. doi:
. [PMID: 2947679] - J Jolivet, L Landry, M F Pinard, J J McCormack, W P Tong, E Eisenhauer. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
Cancer chemotherapy and pharmacology.
1987; 20(2):169-72. doi:
10.1007/bf00253973. [PMID: 2959389] - P L Stetson, W D Ensminger. Determination of plasma trimetrexate levels using gas chromatography-mass spectrometry with selected-ion monitoring.
Journal of chromatography.
1986 Nov; 383(1):69-76. doi:
10.1016/s0378-4347(00)83442-8. [PMID: 2950125] - Y Kano, T Ohnuma, J F Holland. Folate requirements of methotrexate-resistant human acute lymphoblastic leukemia cell lines.
Blood.
1986 Aug; 68(2):586-91. doi:
NULL. [PMID: 2942201] - A F Sobrero, J R Bertino. Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
International journal of cell cloning.
1986 Jan; 4(1):51-62. doi:
10.1002/stem.5530040106. [PMID: 2936838] - F M Balis, C M Lester, D G Poplack. Pharmacokinetics of trimetrexate (NSC 352122) in monkeys.
Cancer research.
1986 Jan; 46(1):169-74. doi:
. [PMID: 2933145] - L K Webster, W P Tong, J J McCormack. Metabolism and biliary excretion of trimetrexate by the isolated perfused rat liver.
Cancer letters.
1985 Oct; 29(1):65-71. doi:
10.1016/0304-3835(85)90124-7. [PMID: 2933139] - J C Drake, C J Allegra, G A Curt, B A Chabner. Competitive protein-binding assay for trimetrexate.
Cancer treatment reports.
1985 Jun; 69(6):641-4. doi:
. [PMID: 3160459] - R C Jackson, D W Fry, T J Boritzki, J A Besserer, W R Leopold, B J Sloan, E F Elslager. Biochemical pharmacology of the lipophilic antifolate, trimetrexate.
Advances in enzyme regulation.
1984; 22(?):187-206. doi:
10.1016/0065-2571(84)90014-1. [PMID: 6236675] - E C Weir, A R Cashmore, R N Dreyer, M L Graham, N Hsiao, B A Moroson, W L Sawicki, J R Bertino. Pharmacology and toxicity of a potent 'nonclassical' 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs.
Cancer research.
1982 May; 42(5):1696-702. doi:
NULL. [PMID: 6461409] - J J Heusner, J J McCormack. Enzymatic assays for 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline, a promising new 'nonclassical' antifolate.
Journal of pharmaceutical sciences.
1981 Jul; 70(7):827-8. doi:
10.1002/jps.2600700737. [PMID: 6455513]
